PT  - JOURNAL ARTICLE
AU  - Cheung, Wing Keung
AU  - Pakzad, Ashkan
AU  - Mogulkoc, Nesrin
AU  - Needleman, Sarah
AU  - Rangelov, Bojidar
AU  - Gudmundsson, Eyjolfur
AU  - Zhao, An
AU  - Abbas, Mariam
AU  - McLaverty, Davina
AU  - Asimakopoulos, Dimitrios
AU  - Chapman, Robert
AU  - Savas, Recep
AU  - Janes, Sam M
AU  - Hu, Yipeng
AU  - Alexander, Daniel C.
AU  - Hurst, John R
AU  - Jacob, Joseph
TI  - Automated airway quantification associates with mortality in idiopathic pulmonary fibrosis
AID  - 10.1101/2023.03.29.23287913
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.03.29.23287913
4099  - http://medrxiv.org/content/early/2023/03/31/2023.03.29.23287913.short
4100  - http://medrxiv.org/content/early/2023/03/31/2023.03.29.23287913.full
AB  - Objectives The study was to examine whether the airway metrics associate with mortality in IPF patients.Methods We performed an observational cohort study (n=90) of IPF patients identified from Ege University Hospital. An airway analysis tool AirQuant calculated median airway segmental intertapering and segmental tortuosity across 2nd to 6th generations of IPF airways. Intertapering measures the difference in median diameter between adjacent airway segments. Tortuosity evaluates the ratio of measured segmental length against direct end- to-end segmental length. Univariable linear regression analyses examined relationships between AirQuant variables, clinical variables and lung function tests. Univariable and Multivariable Cox proportional hazards models estimated mortality risk with the latter adjusted for patient age, gender, smoking status, antifibrotic use, CT usual interstitial pneumonia (UIP) pattern and either forced vital capacity (FVC) or diffusion capacity of carbon monoxide (DLco) if obtained within 3 months of the CT.Results No significant collinearity existed between AirQuant variables and clinical or functional variables. On univariable Cox regression analyses, male gender, smoking history, no antifibrotic use, reduced DLco, reduced segmental intertapering and increased segmental tortuosity associated with increased risk of death. On multivariable Cox regression analyses (adjusted using FVC), segmental intertapering (Hazard Ratio (HR)=0.75, 95% CI=0.66-0.85, p<0.001) and segmental tortuosity (HR=1.74, 95% CI=1.22-2.47, p=0.002) independently associated with mortality. Results were maintained with adjustment using DLco.Conclusions AirQuant generated measures of segmental intertapering and tortuosity independently associate with mortality in IPF patients. Abnormalities in proximal airway generations, which are not typically considered to be abnormal in IPF, have prognostic value.Key PointsAirQuant generates measures of segmental intertapering and tortuosity.Automated airway quantification associates with mortality in IPF independent of established measures of disease severity.Automated airway analysis could be used to refine patient selection for therapeutic trials in IPF.Competing Interest StatementJJ reports fees from Boehringer Ingelheim, Roche, NHSX, Takeda and GlaxoSmithKline unrelated to the submitted work. JJ was supported by Wellcome Trust Clinical Research Career Development Fellowship 209553/Z/17/Z and the NIHR Biomedical Research Centre at University College London. SMJ reports fees from Astra-Zeneca, Bard1 Bioscience, Achilles Therapeutics, and Jansen unrelated to the submitted work. SMJ received assistance for travel to meetings from Astra Zeneca to American Thoracic Conference 2018 and from Takeda to World Conference Lung Cancer 2019 and is the Investigator Lead on grants from GRAIL Inc, GlaxoSmithKline plc and Owlstone. WKC, AP, SN, BR, EG, AZ, MA, DM, DA, RC, RS, YH, DCA, NM, JRH report no relevant conflicts of interest.Funding StatementJJ reports fees from Boehringer Ingelheim, Roche, NHSX, Takeda and GlaxoSmithKline unrelated to the submitted work. JJ was supported by Wellcome Trust Clinical Research Career Development Fellowship 209553/Z/17/Z and the NIHR Biomedical Research Centre at University College London. SMJ reports fees from Astra-Zeneca, Bard1 Bioscience, Achilles Therapeutics, and Jansen unrelated to the submitted work. SMJ received assistance for travel to meetings from Astra Zeneca to American Thoracic Conference 2018 and from Takeda to World Conference Lung Cancer 2019 and is the Investigator Lead on grants from GRAIL Inc, GlaxoSmithKline plc and Owlstone. WKC, AP, SN, BR, EG, AZ, MA, DM, DA, RC, RS, YH, DCA, NM, JRH report no relevant conflicts of interest.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of University College London gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsCIConfidence intervalCOPDChronic obstructive pulmonary diseaseCTComputerised tomographyDLcoDiffusion capacity of carbon monoxideFVCForced vital capacityHRHazard ratioHUHounsfield unitILDInterstitial lung diseaseIPFIdiopathic pulmonary fibrosisPTKPulmonary toolkitSPSSStatistical Product and Service SolutionsSTROBEThe Strengthening the Reporting of Observational Studies in EpidemiologyUIPUsual interstitial pneumonia